Imafuku S, Nakagawa H, Igarashi A, Morita A, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol 2021 Feb 1. doi: 10.1111/1346-8138.15763.
PMID: 33523513